Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial
出版年份 2023 全文链接
标题
Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial
作者
关键词
-
出版物
NATURE MEDICINE
Volume 29, Issue 8, Pages 2133-2141
出版商
Springer Science and Business Media LLC
发表日期
2023-08-01
DOI
10.1038/s41591-023-02465-7
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline
- (2023) Manish A. Shah et al. JOURNAL OF CLINICAL ONCOLOGY
- Comprehensive clinical and molecular characterization of claudin 18.2 expression in advanced gastric or gastroesophageal junction cancer
- (2023) Y. Kubota et al. ESMO Open
- Irreconcilable Differences: The Divorce Between Response Rates, Progression-Free Survival, and Overall Survival
- (2023) Margret Merino et al. JOURNAL OF CLINICAL ONCOLOGY
- Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial
- (2023) Kohei Shitara et al. LANCET
- Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial
- (2022) Yoon-Koo Kang et al. LANCET ONCOLOGY
- Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer
- (2022) Kohei Shitara et al. NATURE
- Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
- (2022) F. Lordick et al. ANNALS OF ONCOLOGY
- FAST: A randomised phase II study of zolbetuximab (IMAB362) plus EOX vs EOX alone for first-line treatment of advanced CLDN18.2 positive gastric and gastro-oesophageal adenocarcinoma
- (2021) U. Sahin et al. ANNALS OF ONCOLOGY
- Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2021) Hyuna Sung et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Biomarker-targeted therapies for advanced-stage gastric and gastro-oesophageal junction cancers: an emerging paradigm
- (2021) Yoshiaki Nakamura et al. Nature Reviews Clinical Oncology
- First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial
- (2021) Yelena Y Janjigian et al. LANCET
- The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2021
- (2021) Feng‐Hua Wang et al. Cancer Communications
- Association of CLDN18 Protein Expression with Clinicopathological Features and Prognosis in Advanced Gastric and Gastroesophageal Junction Adenocarcinomas
- (2021) Antonio Pellino et al. Journal of Personalized Medicine
- Japanese gastric cancer treatment guidelines 2018 (5th edition)
- (2020) Gastric Cancer
- Local and Central Evaluation of HER2 Positivity and Clinical Outcome in Advanced Gastric and Gastroesophageal Cancer—Results from the AGMT GASTRIC-5 Registry
- (2020) Florian Huemer et al. Journal of Clinical Medicine
- Gastric cancer
- (2020) Elizabeth C Smyth et al. LANCET
- A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study
- (2019) O Türeci et al. ANNALS OF ONCOLOGY
- A phase I dose-escalation study of IMAB362 (Zolbetuximab) in patients with advanced gastric and gastro-oesophageal junction cancer
- (2018) Ugur Sahin et al. EUROPEAN JOURNAL OF CANCER
- 103PPrevalence of CLDN18.2, HER2 and PD-L1 in gastric cancer samples
- (2018) D Moran et al. ANNALS OF ONCOLOGY
- Characterization of zolbetuximab in pancreatic cancer models
- (2018) Ӧzlem Türeci et al. OncoImmunology
- Targeted therapies for gastric cancer: failures and hopes from clinical trials
- (2017) Maria Apicella et al. Oncotarget
- Effect of Fluorouracil, Leucovorin, and Oxaliplatin With or Without Onartuzumab in HER2-Negative, MET-Positive Gastroesophageal Adenocarcinoma
- (2017) Manish A. Shah et al. JAMA Oncology
- Gastric cancer
- (2016) Eric Van Cutsem et al. LANCET
- Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial
- (2014) Hansjochen Wilke et al. LANCET ONCOLOGY
- Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial
- (2013) Charles S Fuchs et al. LANCET
- Tight junction-related human diseases
- (2013) Norimasa Sawada PATHOLOGY INTERNATIONAL
- Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis
- (2012) Y. Y. Janjigian et al. ANNALS OF ONCOLOGY
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
- (2010) Yung-Jue Bang et al. LANCET
- Claudin-18 Splice Variant 2 Is a Pan-Cancer Target Suitable for Therapeutic Antibody Development
- (2008) U. Sahin et al. CLINICAL CANCER RESEARCH
- Safety and Efficacy of Oxaliplatin and Fluoropyrimidine Regimens With or Without Bevacizumab As First-Line Treatment of Metastatic Colorectal Cancer: Results of the TREE Study
- (2008) Howard S. Hochster et al. JOURNAL OF CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search